AmacaThera doses First In Human Study to Evaluate, AMT-143, for Non-opioid Treatment of Postoperative Pain

Posted on by

TORONTO, 15 mai 2024 /PRNewswire/ — AmacaThera Inc, une société de biotechnologie en phase clinique spécialisée dans le développement de formulations avancées d’hydrogel à libération prolongée, a administré à son premier sujet humain le AMT-143, le principal actif de la société dans la…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.